Yuanjun Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuanjun Cheng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Guohui Zang
Department of Cardiothoracic Surgery, People’s Hospital of Chizhou, Chizhou, China
4 shared publicationsJie Yao
Department of Cardiothoracic Surgery, People’s Hospital of Chizhou, Chizhou, China
4 shared publicationsQianru Fang
Department of Obstetrics, People’s Hospital of Chizhou, Chizhou, China
3 shared publications- Yongbing Chen
Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
3 shared publications Bin Chen
Department of Cardiothoracic Surgery, People’s Hospital of Chizhou, Chizhou, China
2 shared publications- Shanzhou Duan
Department of Thoracic Surgery, The Second Affiliated Hospital of SoochowUniversity, Suzhou, China
2 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1) , 1378
Publisher Correction: MISP promotes the progression of lung adenocarcinoma through inhibition of the Hippo signaling pathway
- 26 September 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1) , 1378
Open AccessPublisher Correction: MISP promotes the progression of lung adenocarcinoma through inhibition of the Hippo signaling pathway
- Open Access
- 17 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2116
MISP promotes the progression of lung adenocarcinoma through Inhibition of the Hippo signaling pathway
Background Globally, lung cancer is a malignant tumor with the highest morbidity and mortality rate, of which lung adenocarcinoma (LUAD) is the most common pathological type, accounting for about 40% of all cases. This study aims to investigate the impact and molecular mechanisms of mitotic spindle positioning (MISP) on the occurrence and progression of LUAD. Methods The expression level of MISP were evaluated by qPCR and Western blotting. Hippo signaling-related protein levels were measured by Western blotting. Co-immunoprecipitation assay was applied to assess the interaction between MISP and MST1. The roles of MISP in LUAD cells were determined through CCK-8 assay, transwell migration/invasion assay, and flow cytometric analysis. A xenograft tumor model (n = 6) was established to calculate the effect of MISP in vivo. Results MISP expression was significantly higher in LUAD tissues compared to normal tissues. MISP overexpression promoted LUAD cell proliferation and migration in in vitro models, as well as tumor growth and metastasis in LUAD animal models. Western blotting demonstrated that MISP overexpression increased the expression of YAP, TAZ and CYR61, and decreased the expression of MST1 and phosphorylated YAP, thereby blocking the Hippo signaling pathway. While MISP knockdown had the opposite effect. Mechanistic experiments revealed that MISP directly interacts with MST1, thereby inhibiting Hippo signaling. Conclusions In conclusion, our study reveals a novel discovery that MISP promotes the growth and invasion of LUAD cells by interacting with MST1 and suppressing the Hippo pathway.
- 17 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2116
Open AccessMISP promotes the progression of lung adenocarcinoma through Inhibition of the Hippo signaling pathway
Background Globally, lung cancer is a malignant tumor with the highest morbidity and mortality rate, of which lung adenocarcinoma (LUAD) is the most common pathological type, accounting for about 40% of all cases. This study aims to investigate the impact and molecular mechanisms of mitotic spindle positioning (MISP) on the occurrence and progression of LUAD. Methods The expression level of MISP were evaluated by qPCR and Western blotting. Hippo signaling-related protein levels were measured by Western blotting. Co-immunoprecipitation assay was applied to assess the interaction between MISP and MST1. The roles of MISP in LUAD cells were determined through CCK-8 assay, transwell migration/invasion assay, and flow cytometric analysis. A xenograft tumor model (n = 6) was established to calculate the effect of MISP in vivo. Results MISP expression was significantly higher in LUAD tissues compared to normal tissues. MISP overexpression promoted LUAD cell proliferation and migration in in vitro models, as well as tumor growth and metastasis in LUAD animal models. Western blotting demonstrated that MISP overexpression increased the expression of YAP, TAZ and CYR61, and decreased the expression of MST1 and phosphorylated YAP, thereby blocking the Hippo signaling pathway. While MISP knockdown had the opposite effect. Mechanistic experiments revealed that MISP directly interacts with MST1, thereby inhibiting Hippo signaling. Conclusions In conclusion, our study reveals a novel discovery that MISP promotes the growth and invasion of LUAD cells by interacting with MST1 and suppressing the Hippo pathway.
- Open Access
- 1 December 2022
- Published by Impact Journals, LLC in Aging
- Vol. 14 (23) , 9617-9631
A circadian rhythm-related biomarker for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
Lung adenocarcinoma (LUAD) remains a major reason of cancer-associated mortality globally, and there exists a lack of indicators for survival in LUAD patients. Therefore, it is clinically required to obtain a novel prognostically indicator for guiding clinical management. In this study, we established a circadian rhythm (CR) related signature by a combinative investigation of multiple datasets. The newly-established signature showed an acceptable ability to predict survival and could serve as an independent indicator for prognosis. Moreover, the newly-established signature was critically associated with tumor malignancy, including proliferation, invasion, EMT and metastasis. The newly-established signature was predictive of response to immune checkpoint blockade. Collectively, we established a CR-related gene signature that could forecast survival, tumor malignancy and therapeutic response; our findings could help guiding clinical management.
- 1 December 2022
- Published by Impact Journals, LLC in Aging
- Vol. 14 (23) , 9617-9631
Open AccessA circadian rhythm-related biomarker for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
Lung adenocarcinoma (LUAD) remains a major reason of cancer-associated mortality globally, and there exists a lack of indicators for survival in LUAD patients. Therefore, it is clinically required to obtain a novel prognostically indicator for guiding clinical management. In this study, we established a circadian rhythm (CR) related signature by a combinative investigation of multiple datasets. The newly-established signature showed an acceptable ability to predict survival and could serve as an independent indicator for prognosis. Moreover, the newly-established signature was critically associated with tumor malignancy, including proliferation, invasion, EMT and metastasis. The newly-established signature was predictive of response to immune checkpoint blockade. Collectively, we established a CR-related gene signature that could forecast survival, tumor malignancy and therapeutic response; our findings could help guiding clinical management.
- Open Access
- 21 March 2022
- Published by Springer Nature in Research Square
A cancer stemness-related eight-gene signature for predicting prognosis and malignant degree of lung adenocarcinoma
To identify a cancer stemness-related prognostic signature, we analyzed RNA-seq data of patients with lung adenocarcinoma from the TCGA and GEO cohort using univariate Cox and LASSO analysis. Eight genes (PLEK2, GPX8, TCN1, PERP, CD79A, PAX5, FSCN1, and CNNM1) were eventually identified to develop a cancer stemness-related signature. AUCs for 5-year overall survival were 0.681, 0.673, and 0.774 in the training, validation, and test sets, respectively. Kaplan-Meier curve analysis showed that the high-risk group has a poor survival as compared with the low-risk group in the training set, validation set, and test set, respectively (P < 0.05). Six genes (PLEK2, GPX8, TCN1, PERP, FSCN1, and CNNM1) were significantly upregulated in the cancerous tissue compared with in the normal tissue (P < 0.001), and correlated with an unwanted prognosis (P < 0.05). We constructed a prognostic nomogram combining the cancer stemness-related signature with TNM staging to precisely assess the prognosis of the patient with lung adenocarcinoma. Finally, we observed that the stemness-related gene signature also could predict the malignant levels of lung adenocarcinoma possibly via hypoxia, epithelial-mesenchymal transition and angiogenesis. Conclusively, this study developed a novel cancer stemness-related gene signature, and identified six pivotal genes which can serve as potential therapeutic targets in the treatment of lung cancer.
- 21 March 2022
- Published by Springer Nature in Research Square
Open AccessA cancer stemness-related eight-gene signature for predicting prognosis and malignant degree of lung adenocarcinoma
To identify a cancer stemness-related prognostic signature, we analyzed RNA-seq data of patients with lung adenocarcinoma from the TCGA and GEO cohort using univariate Cox and LASSO analysis. Eight genes (PLEK2, GPX8, TCN1, PERP, CD79A, PAX5, FSCN1, and CNNM1) were eventually identified to develop a cancer stemness-related signature. AUCs for 5-year overall survival were 0.681, 0.673, and 0.774 in the training, validation, and test sets, respectively. Kaplan-Meier curve analysis showed that the high-risk group has a poor survival as compared with the low-risk group in the training set, validation set, and test set, respectively (P < 0.05). Six genes (PLEK2, GPX8, TCN1, PERP, FSCN1, and CNNM1) were significantly upregulated in the cancerous tissue compared with in the normal tissue (P < 0.001), and correlated with an unwanted prognosis (P < 0.05). We constructed a prognostic nomogram combining the cancer stemness-related signature with TNM staging to precisely assess the prognosis of the patient with lung adenocarcinoma. Finally, we observed that the stemness-related gene signature also could predict the malignant levels of lung adenocarcinoma possibly via hypoxia, epithelial-mesenchymal transition and angiogenesis. Conclusively, this study developed a novel cancer stemness-related gene signature, and identified six pivotal genes which can serve as potential therapeutic targets in the treatment of lung cancer.
- Open Access
- 24 February 2021
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 8
High Expression of Tumor Abnormal Protein Preoperatively Predicts Poor Prognosis of Patients With Esophageal Squamous Cell Carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) acts as a fatal malignant tumor among human beings and is marked by late-stage diagnosis, frequent recurrence, metastasis, and therapy resistance. Tumor abnormal protein (TAP) remarkably affects cancer development and progression of human cancers. TAP has been shown to be a biomarker for gastric and lung cancer progression. Nevertheless, the clinical value exhibited by TAP for ESCC has not been well-explained in the current literature.Methods: The present study included 183 ESCC cases who received surgical resection and 183 cases who had normal physical checkup from March 2013 to January 2015 at the People's Hospital of Chizhou, and used the TAP detection agent for evaluating the TAP relative level.Results: As found, ESCC patients presented an obviously higher TAP expression relative to cases who had normal physical checkup. Moreover, TAP expression was significantly downregulated after surgery. Furthermore, the TAP expression was correlated with gender, smoking, pathologic differentiation, and pN stage, but not with age, tumor location, surgical type, pT stage, and vascular invasion. High expression of TAP was significantly correlated with poorer overall survival (OS) rate in ESCC patients. TAP was an independent prognostic predictor in ESCC patients, based on the multivariate survival analysis.Conclusion: The study reveals how TAP upregulation promotes ESCC malignant progression, and concludes that TAP acts as the therapeutic target and potential biomarker specific to ESCC.
- 24 February 2021
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 8
Open AccessHigh Expression of Tumor Abnormal Protein Preoperatively Predicts Poor Prognosis of Patients With Esophageal Squamous Cell Carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) acts as a fatal malignant tumor among human beings and is marked by late-stage diagnosis, frequent recurrence, metastasis, and therapy resistance. Tumor abnormal protein (TAP) remarkably affects cancer development and progression of human cancers. TAP has been shown to be a biomarker for gastric and lung cancer progression. Nevertheless, the clinical value exhibited by TAP for ESCC has not been well-explained in the current literature.Methods: The present study included 183 ESCC cases who received surgical resection and 183 cases who had normal physical checkup from March 2013 to January 2015 at the People's Hospital of Chizhou, and used the TAP detection agent for evaluating the TAP relative level.Results: As found, ESCC patients presented an obviously higher TAP expression relative to cases who had normal physical checkup. Moreover, TAP expression was significantly downregulated after surgery. Furthermore, the TAP expression was correlated with gender, smoking, pathologic differentiation, and pN stage, but not with age, tumor location, surgical type, pT stage, and vascular invasion. High expression of TAP was significantly correlated with poorer overall survival (OS) rate in ESCC patients. TAP was an independent prognostic predictor in ESCC patients, based on the multivariate survival analysis.Conclusion: The study reveals how TAP upregulation promotes ESCC malignant progression, and concludes that TAP acts as the therapeutic target and potential biomarker specific to ESCC.
- Open Access
- 1 March 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 1941-1946
Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer
Background: The most common cancer among humans is lung cancer. Non-small cell lung cancer (NSCLC) comprises the majority of these cases. In the development and progression of cancers across the spectrum, tumor abnormal protein (TAP) plays crucial roles. Additionally, in the advancement of the bladder and colorectal cancers, the involvement of glycoproteins like TAP is present. However, it is worth noting that current literature has yet to clarify the clinical significance of the TAP in NSCLC. Methods: In the present study, to evaluate the relative level of TAP, we utilized a TAP detection agent in 154 cases of NSCLC and normal patients who underwent surgical resection anytime from March 2013 to January 2019 at the People’s Hospital of Chizhou. Results: Our results demonstrated that in NSCLC patients, the expression level of TAP was significantly higher than in normal patients. Moreover, after surgery, TAP expression was significantly downregulated in NSCLC patients. TAP expression is associated with an array of factors, which include the patient’s sex, history of smoking use, tumor size, pTNM, distant cancer, metastasis of lymph nodes, invasive and aggressive indicator pleural invasion, and differentiation degree of NSCLC. Additionally, TAP has no association with the patient’s age, history of drinking, location of the tumor, hypertension, and diabetes. In NSCLC patients, a poor overall survival rate within 5 years is significantly correlated with the increased TAP expression. For NSCLC patients, an independent prognostic factor is the TAP, which is confirmed using the multivariate survival analysis. Conclusion: In the malignant progression of NSCLC, our results demonstrate how the promoting role of the upregulated TAP expression takes place. Hence, a therapeutic aim for NSCLC and a potential biomarker for NSCLC progress is a TAP.
- 1 March 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 1941-1946
Open AccessIncreased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer
Background: The most common cancer among humans is lung cancer. Non-small cell lung cancer (NSCLC) comprises the majority of these cases. In the development and progression of cancers across the spectrum, tumor abnormal protein (TAP) plays crucial roles. Additionally, in the advancement of the bladder and colorectal cancers, the involvement of glycoproteins like TAP is present. However, it is worth noting that current literature has yet to clarify the clinical significance of the TAP in NSCLC. Methods: In the present study, to evaluate the relative level of TAP, we utilized a TAP detection agent in 154 cases of NSCLC and normal patients who underwent surgical resection anytime from March 2013 to January 2019 at the People’s Hospital of Chizhou. Results: Our results demonstrated that in NSCLC patients, the expression level of TAP was significantly higher than in normal patients. Moreover, after surgery, TAP expression was significantly downregulated in NSCLC patients. TAP expression is associated with an array of factors, which include the patient’s sex, history of smoking use, tumor size, pTNM, distant cancer, metastasis of lymph nodes, invasive and aggressive indicator pleural invasion, and differentiation degree of NSCLC. Additionally, TAP has no association with the patient’s age, history of drinking, location of the tumor, hypertension, and diabetes. In NSCLC patients, a poor overall survival rate within 5 years is significantly correlated with the increased TAP expression. For NSCLC patients, an independent prognostic factor is the TAP, which is confirmed using the multivariate survival analysis. Conclusion: In the malignant progression of NSCLC, our results demonstrate how the promoting role of the upregulated TAP expression takes place. Hence, a therapeutic aim for NSCLC and a potential biomarker for NSCLC progress is a TAP.